Preview Mode Links will not work in preview mode

PCSS Podcast

The PCSS Podcast discusses up-to-date pain medicine and substance use disorder topics with the goal of increasing the general education of healthcare providers. These podcasts are not designated for CME credit.

Visit pcssNOW.org to learn more.

Funding for this initiative was made possible (in part) by grant nos. 5H79TI025595-03, 5U79TI026556-02 and 3U79TI026556-02S1 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human ServicesÍž nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

May 22, 2017

Today we will be talking about the use of naltrexone for the treatment of opioid use disorder therapy. Naltrexone is an opioid blocker, or antagonist, that has limited prevalence of use compared with buprenorphine, a partial agonist, and methadone, a long-acting agonist. Joining us for this conversation is Dr. Adam Bisaga, an academic psychiatrist, educator and clinician.  He is a Professor of Psychiatry at the Columbia University Medical Center, and a Research Scientist at the New York State Psychiatric Institute. He was a recipient of a Career Development Award and a Principal Investigator on grants funded by the National Institute of Drug Abuse. His research interests include development of human laboratory and clinical trial models for testing medications to treat substance use disorders, including trials to improve effectiveness of antagonist-based treatment of opioid use disorder. Dr. Bisaga publishes and lectures in the area of addiction research and he is a member of the editorial board of the journal Addiction.


sinching chiu
over a year ago

good and useful discussion